XML 48 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
The Company (Details)
$ in Thousands
1 Months Ended 9 Months Ended
Aug. 23, 2018
USD ($)
shares
Apr. 20, 2017
USD ($)
shares
Aug. 31, 2014
member_state
Sep. 30, 2018
USD ($)
product
country
Dec. 31, 2017
USD ($)
Aug. 31, 2015
Long-term debt            
Number of products | product       2    
Number of member states of the European Economic Area | member_state     31      
Development milestone payments which the entity is obligated to pay       $ 4,500    
Retained earnings (accumulated deficit)       $ (890,593) $ (814,108)  
Convertible debt | 3.00% Convertible senior notes due 2022            
Long-term debt            
Interest rate           3.00%
Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC            
Long-term debt            
Cash consideration   $ 75,000        
Equity Interest Issued, number of shares (in shares) | shares   6,683,598        
Numerator for calculation of number of shares of equity interests issued to acquire entity   $ 65,000        
Trading day period   15 days        
Development milestone payments which the entity is obligated to pay   $ 50,000        
Translarna            
Long-term debt            
Number of countries | country       25    
Agilis            
Long-term debt            
Cash consideration $ 49,221          
Equity Interest Issued, number of shares (in shares) | shares 3,500,907          
Numerator for calculation of number of shares of equity interests issued to acquire entity $ 150,000          
Trading day period 10 days          
Development milestone payments which the entity is obligated to pay $ 40,000     $ 40,000    
Agilis | Non-collaborative Arrangement Transactions            
Long-term debt            
Development milestone payments which the entity is obligated to pay $ 40,000     $ 40,000